BRAF and hepatocellular carcinoma: This supports previous studies establishing an association of IFN receptor levels with the antiproliferative efficacy of IFN in HCC [27, 102], and is in line with reports on IFNAR downregulation in advancing bladder cancers [103], and also BRAF-mutated melanoma [104].